Hangzhou Market Supervision Department Reports on Anlibu's "Height Increase Scam": A case has been filed against the company.

MaticHoleFiller · 2026-03-18T07:11:21+00:00

In 2026, CCTV's "315 Gala" exposed Hangzhou Anli Health Management Co., Ltd.'s "height increase scam," prompting the Market Supervision and Administration Bureau to launch an investigation and pledge to crack down severely on practices that harm consumer rights.

MaticHoleFiller

2026-03-18 07:11:21

Abstract generation in progress

Special Topic: Improving Consumer Quality — Focus on the 2026 “315 Gala”

Stock trading insights from Golden Kylin Analysts Reports—authoritative, professional, timely, comprehensive—helping you uncover potential thematic opportunities!

Hangzhou High-Tech (Rights Protection) Zone (Binjiang) Market Supervision Administration issued a report: The 2026 CCTV “3.15 Gala” exposed the “height increase scam” by Hangzhou Anlishen Health Management Co., Ltd. Our bureau attaches great importance, promptly arrived at the scene to conduct lawful investigations and handling. We have filed a case against the company and are collecting evidence to substantiate the facts. Moving forward, we will handle the case strictly in accordance with laws and regulations based on the investigation results. Thank you to the media and all sectors of society for their supervision. Our bureau will resolutely crack down on illegal activities that infringe on consumer rights and strengthen consumer protection.

Disclaimer: This message is reproduced from Sina’s partner media. Sina.com publishes this article to share more information and does not imply endorsement of its views or verification of its content. The article is for reference only and does not constitute investment advice. Investors operate at their own risk.

Massive information, precise analysis, all on Sina Finance APP

Editor: Wang Xuning

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.